New Data for Intralink-Spine’s Réjuve Treatment for Low Back Pain

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

“We’ve demonstrated the safety of this device, and it has performed as expected. The dramatic pain reduction in these patients correlated with some objective measures: there was an average increase in lumbar range of motion of 9 degrees and there was a statistically significant 25% increase in treated level lordosis, based on kinematic data analysis performed by Medical Metrics Inc. Decreased lumbar lordosis is known to be related to disc degeneration and back pain, especially when standing,” states Dr. Tom Hedman, Ph.D., the inventor and Adjunct Associate Professor in the F. Joseph Halcomb III, M.D. Department of Biomedical Engineering at the University of Kentucky.

Additional findings at the six-month juncture from its early safety and feasibility study, Intralink-Spine, Inc. (ILS) indicates that the Réjuve™ System effectively eliminates or reduces low back pain.

“We’ve demonstrated the safety of this device, and it has performed as expected. The dramatic pain reduction in these patients correlated with some objective measures: there was an average increase in lumbar range of motion of 9 degrees and there was a statistically significant 25% increase in treated level lordosis, based on kinematic data analysis performed by Medical Metrics Inc. Decreased lumbar lordosis is known to be related to disc degeneration and back pain, especially when standing,” states Dr. Tom Hedman, Ph.D., the inventor and Adjunct Associate Professor in the F. Joseph Halcomb III, M.D. Department of Biomedical Engineering at the University of Kentucky.

“I was also excited to see that the only symptomatic disc in these first few low back pain patients that was shown to be clinically unstable pre-treatment (QSI = 2.5, meaning the instability as quantified by translation per degree of rotation (TPDR) was 2.5 standard deviations above the mean for an asymptomatic, radiographically normal population) was effectively stabilized by the Réjuve treatment. This previously symptomatic and unstable segment was asymptomatic (no pain and no disability at 1 month through 6 months) and stable with a normal TPDR (QSI = -0.1). This result illustrates and affirms one of the mechanisms for pain relief associated with this product,” says Dr. Hedman.

“After a six-month period, 80% of patients had excellent results (pain and disability reduced >50%). Patient data are also showing the Réjuve Treatment is “fast acting” – treatment effects seen at 2-weeks post-procedure continued or improved through 6-months in 80% of patients treated. Think of it, the positive effects of Réjuve are both rapid and long-lasting,” says Lyle Hawkins, CEO of Intralink-Spine, Inc. “Low back pain (LBP) is a challenging condition to treat, which is why we’re excited about our data thus far and another reason we’re excited about our studies underway in Malaysia and Canada.”

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.